GKOS News and Press, Glaukos Corporation From 05/06/24

2024-05-06 10:07:39 ET Glaukos ( NYSE: GKOS ) stock is up on upgrade to Buy from Hold at Jefferies on strong iDose Outlook.... Read the full article on Seeking Alpha For further details see: Glaukos rises on upgrade to Buy at Jefferies

2024-05-06 04:00:04 ET Michael Sarcone from Jefferies issued a price target of $125.00 for GKOS on 2024-05-06 01:02:00. The adjusted price target was set to $125.00. At the time of the announcement, GKOS was trading at $106.51. The overall price target consensus is at $7...

2024-05-01 20:42:08 ET Glaukos Corporation (GKOS) Q1 2024 Earnings Conference Call May 01, 2024 04:30 PM ET Company Participants Chris Lewis - Vice President of IR & Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurm...

2024-05-01 17:12:51 ET More on Glaukos Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript Glaukos Q1 2024 Earnings Preview Glaukos gains on permanent J-code for iDose TR Seeking Alpha’s Quant Rating on Glaukos Historical earnings data ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: ...

2024-05-01 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...

Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $102.98. So far today, approximately 56,347 shares have been exchanged, as compared to an average 30-day volume of 529.81k shares. Glaukos Corporation, an ophthalmic medical technology a...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company&#...

2024-04-14 17:56:08 ET More on Boston Scientific, CONMED, etc. ResMed: Not A Sleeper Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash Boston Scientific: The Market's Newest Mega-Cap Needs A Breather Mizuho sees ResMed as 'overwhelming ben...